Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
NEKTAR THERAPEUTICS
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
March 28, 2026
Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
March 20, 2026
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
March 12, 2026
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025
December 16, 2025
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 7, 2025
←
Previous Page
1
2